Goyder C. et al, (2020), BMJ Open, 10
Assessing treatment benefits with CDK4/6i+ET for hormone receptor-positive advanced breast cancer: A network meta analysis.
De Mello RA. et al, (2019), JOURNAL OF CLINICAL ONCOLOGY, 37
Roope LSJ. et al, (2019), Science, 364
Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer.
Aguiar PN. et al, (2019), Einstein (Sao Paulo), 17
Impact of point-of-care C reactive protein in ambulatory care: A systematic review and meta-analysis
Verbakel JY. et al, (2019), BMJ Open, 9
The clinical utility of point-of-care tests for influenza in ambulatory care: A systematic review and meta-analysis
Lee JJ. et al, (2019), Clinical Infectious Diseases, 69, 24 - 33
Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis.
Tan PS. et al, (2018), Prostate Cancer Prostatic Dis, 21, 516 - 523
Network metanalysis and cost-effectiveness of abiraterone, docetaxel or placebo plus androgen deprivation therapy (ADT) for hormone-sensitive advanced prostate cancer.
Aguiar PN. et al, (2018), JOURNAL OF CLINICAL ONCOLOGY, 36
Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants.
Tan PS. et al, (2018), Lung Cancer, 115, 84 - 88
Indirect Comparison between Immune-Checkpoint Inhibitors for 2nd Line Non-Small Cell Lung Cancer - a Network Meta-Analysis
Tan P. et al, (2017), JOURNAL OF THORACIC ONCOLOGY, 12, S2149 - S2149
Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation, histology and response to previous induction
Tan PS. et al, (2015), European Journal of Cancer, 51, 2330 - 2344
Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations
Haaland B. et al, (2014), Journal of Thoracic Oncology, 9, 805 - 811
Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel—an Indirect Comparison
Tan PS. et al, (2014), Clinical Medicine Insights: Oncology, 8, CMO.S13671 - CMO.S13671
A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer
Tan PS. et al, (2013), Breast Cancer Research and Treatment, 138, 961 - 965